WO2022005169A1 - Composition injectable comprenant des dérivés de gnrh - Google Patents

Composition injectable comprenant des dérivés de gnrh Download PDF

Info

Publication number
WO2022005169A1
WO2022005169A1 PCT/KR2021/008187 KR2021008187W WO2022005169A1 WO 2022005169 A1 WO2022005169 A1 WO 2022005169A1 KR 2021008187 W KR2021008187 W KR 2021008187W WO 2022005169 A1 WO2022005169 A1 WO 2022005169A1
Authority
WO
WIPO (PCT)
Prior art keywords
sorbitan
weight
injectable composition
group
composition
Prior art date
Application number
PCT/KR2021/008187
Other languages
English (en)
Korean (ko)
Inventor
고진영
정성범
노상명
임종래
Original Assignee
주식회사 종근당
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 종근당 filed Critical 주식회사 종근당
Priority to CN202180046461.0A priority Critical patent/CN115867258A/zh
Priority to AU2021299156A priority patent/AU2021299156A1/en
Priority to US18/010,399 priority patent/US20230248801A1/en
Priority to CA3180468A priority patent/CA3180468A1/fr
Priority to EP21833046.2A priority patent/EP4173614A1/fr
Priority to MX2022016437A priority patent/MX2022016437A/es
Priority to JP2022581316A priority patent/JP2023532107A/ja
Priority to BR112022025817A priority patent/BR112022025817A2/pt
Publication of WO2022005169A1 publication Critical patent/WO2022005169A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Definitions

  • the present invention relates to a sustained-release depot formulation containing a GnRH derivative as a pharmacologically active substance and an injectable composition comprising the same.
  • a representative pharmacologically active substance suitable to be designed in the form of a sustained-release preparation includes a GnRH derivative.
  • GnRH derivatives can be used for prostate cancer, breast cancer, ovarian cancer, endometriosis, fibroids of the uterus, polycystic ovaryosis, hirsutism, precocious puberty, gonadotropic pituitary adenoma, sleep apnea, irritable bowel syndrome, and premenstrual syndrome.
  • sex hormone-dependent diseases such as benign prostatic hyperplasia or infertility.
  • Lupron ® Depot which contains leuprolide acetate as a pharmacologically active substance.
  • Lupron ® Depot is widely used as an intramuscular and subcutaneous injection using biodegradable PLGA [poly(lactic-co-glycolic acid)] microspheres as a sustained-release substrate.
  • biodegradable PLGA poly(lactic-co-glycolic acid)] microspheres as a sustained-release substrate.
  • PLGA microspheres stay in the body for a certain period of time and are decomposed into lactic acid and glycolic acid to continuously release the encapsulated pharmacologically active substance, thereby exhibiting a sustained-release effect (US Patent No. 5,480,656).
  • the PLGA microsphere manufacturing process has disadvantages in that it is complicated and difficult, and the encapsulation efficiency of the pharmacologically active material is significantly lowered.
  • PLGA fine particles are difficult to filter and melt at a temperature of 40° C. or higher, the method generally used for aseptic treatment cannot be applied, so there is a difficulty in performing the process under highly sterile conditions.
  • it is necessary to additionally perform a complicated process in which two or more different types of microspheres are prepared and mixed in order to create an ideal sustained-release pattern International Patent Publication No. WO 2005/074896
  • the economic cost due to the inefficient process increases. .
  • acetic acid impurities and acid decomposition substances from PLGA microspheres cause inflammatory reactions and decrease in cell proliferation rate (K. Athanasiou, GG Niederauer, and CM Agrawal, Biomaterials, 17, 93 (1996)), 10 ⁇ 100 Due to the nature of the product, which requires a large amount of intramuscular and subcutaneous administration by suspending microspheres in an aqueous solution, pain or tissue damage occurs at the injection site.
  • the GnRH derivative (leuprolide acetate) sustained-release injection introduced to compensate for the shortcomings of the PLGA microsphere sustained-release formulation is ELIGARD ® .
  • ELIGARD is widely marketed as a subcutaneous injection using poly(DL-lactide-co-glycolide) and a GnRH derivative (leuprolide acetate) having a protected carboxyl terminal group dissolved in N-methyl-2-pyrrolidone (NMP).
  • NMP N-methyl-2-pyrrolidone
  • Eli guard main ® is administered by subcutaneous after dissolving the biodegradable polymer a polar aprotic solution to prepare a liquid composition, and some improvement in the disadvantages of solid dosage forms having PLGA microspheres (U.S. Patent No. 6773714 No.).
  • the product does not provide a complete pre-filled injection device, so it is very convenient to use and has disadvantages in that drug stability in a mixed solution is low.
  • the kit provided by this product consists of two connectable syringes and devices for mixing, preparation and injection.
  • a complicated process of about 10 steps or more is required to prepare the final mixed solution, and there is a difficulty in completing the preparation and administration within 30 minutes.
  • the product requires a separate refrigeration storage device due to storage conditions, and if the final mixed solution cannot be refrigerated, it cannot be used for more than 5 days.
  • the formulation did not improve the high initial drug release phenomenon, which is a general disadvantage of PLGA formulations, but rather showed a higher initial drug concentration than Lupron ® Depot, a PLGA particulate formulation (US Patent No. 6,773,714).
  • Initial drug concentrations significantly above the drug functional range are not functionally or toxicologically desirable.
  • GnRH derivatives are a mechanism in which sex hormone secretion is temporarily increased at the beginning of administration and then down-regulated after a certain point in time, excessive initial drug release is a factor that must be avoided.
  • International Patent Publication No. WO 2005/117830 discloses at least one neutral diacilipid and/or tocopherol, at least one phospholipid, and at least one biocompatible and oxygen-containing discloses an initial formulation containing a low-viscosity organic solvent that It discloses an initial formulation containing. These formulations do not produce lactic acid or glycolic acid degradation products of the polymer system, so pain or inflammation at the injection site is not accompanied, and pharmacologically active substances are continuously released in vivo for about 4 weeks.
  • the diacyl lipid which is a key component of the formulation, is a material that is not generally used as an excipient for pharmaceuticals and is not sufficiently secured, and there is a problem that an organic solvent that causes deterioration of the activity of some pharmacologically active substances must be used.
  • the present inventors a) sorbitan unsaturated fatty acid ester (sorbitan unsaturated fatty acid ester); b) phospholipids; c) a liquid crystal strengthening agent; and d) a pharmaceutical composition comprising a GnRH derivative as a pharmacologically active substance, in a lipid liquid state in the absence of an aqueous fluid, and forming liquid crystals in an aqueous fluid (Korean Application No. 10-2012-0157583) ).
  • the sustained-release lipid initial formulation according to the present invention has equal or superior safety and biodegradability in animal testing (in vivo) compared to the existing initial formulation, and the pharmaceutical composition comprising a pharmacologically active substance releases the drug was confirmed.
  • the present inventors repeated research and added water to the initial sustained-release lipid initial preparation containing the GnRH derivative in advance to form a liquid crystal gel immediately after administration of the liquid injection, thereby significantly improving the initial release rate and sustained-release properties of the drug.
  • Depot formulation invention was completed.
  • polyoxyethylene sorbitan fatty acid ester and polyoxyethylene vitamin E derivative are substances in which polyoxyethylene, a hydrophilic polymer, is combined with sorbitan fatty acid ester and vitamin E, respectively, and the structure of the original sorbitan fatty acid ester and vitamin E is different. It is completely different and different from the constituents of the present invention in that it is a material used as a hydrophilic surfactant using the properties of polyoxyethylene.
  • WO 2012/160212 discloses 20-80% of at least one diacilipid and/or tocopherol, 20-80% of at least one phospholipid, and 5-35% of at least one biocompatible organic An alcohol solvent, an aqueous solution of 20% or less, and at least one dual amylin receptor/GLP-1 receptor agonist drug are disclosed in the initial formulation. Disclosed is an initial formulation comprising one phospholipid, a low-viscosity organic solvent containing at least one oxygen, and at least one opioid drug. These formulations do not produce lactic acid or glycolic acid degradation products of the polymer system, so pain or inflammation at the injection site is not accompanied, and pharmacologically active substances are continuously released in vivo.
  • WO 2005/074896 discloses a composition that releases a GnRH agonist or a salt thereof for a long period of time as PLGA microcapsules containing an aqueous solution.
  • the composition of this patent is different from the present invention in that the composition of the patent is a PLGA microparticle formulation, which is a sustained release formulation completely different from the present invention, and the aqueous channel inside the PLGA microparticles is used for containing a water-soluble drug.
  • Patent Document 1 International Patent Publication No. WO 2005/074896
  • Patent Document 2 International Patent Publication No. WO 2005/117830
  • Patent Document 3 International Patent Publication No. WO 2006/075125
  • Patent Document 4 International Patent Publication No. WO 2012/160212
  • Patent Document 5 US Registered Patent Publication No. 5,480,656
  • Patent Document 6 US Registered Patent Publication No. 6,773,714
  • Patent Document 7 US Registered Patent Publication No. 7,731,947
  • Patent Document 8 US Registered Patent Publication No. 7,871,642
  • Patent Document 9 US Registered Patent Publication No. 5,888,533
  • An object of the present invention is to remarkably improve safety by using a sorbitan unsaturated fatty acid ester having two or more -OH (hydroxy groups) in a polar head group as a composition, and it is liquid in the absence of aqueous fluid, so it is easy to apply a pharmaceutical formulation in a dosage form.
  • An object of the present invention is to provide an injectable composition that increases the sustained-release properties of a GnRH derivative used as a pharmacologically active material in vivo by forming a liquid crystal in an aqueous fluid phase.
  • An object of the present invention is to remarkably improve safety by using a sorbitan unsaturated fatty acid ester having two or more -OH (hydroxy groups) in a polar head group as a composition, and it is liquid in the absence of aqueous fluid, so it is easy to apply a pharmaceutical formulation in a dosage form.
  • An object of the present invention is to provide an injectable composition that increases the sustained-release properties of a GnRH derivative used as a pharmacologically active material in vivo by forming a liquid crystal in an aqueous fluid phase.
  • Another object of the present invention is to provide an injectable composition capable of improving injection pain, inflammation, and high initial release concentration, which the conventional sustained-release formulations cannot overcome because it is injectable in a liquid form.
  • the present invention provides a) a sorbitan unsaturated fatty acid ester having two or more -OH (hydroxyl) groups in the polar head group; b) phospholipids; c) a liquid crystal hardener that does not have an ionizer, and the hydrophobic portion has a triacyl group having 15 to 40 carbon atoms or a carbon ring structure; d) water; and e) a gonadotropin-releasing hormone (GnRH) derivative as a pharmacologically active substance, which is liquid before injection and forms liquid crystals after injection.
  • GnRH gonadotropin-releasing hormone
  • R has 4 to 30 carbon atoms and means an alkyl ester group including at least one double bond.
  • the conventional liquid crystalline material is difficult to apply to drug development due to the following disadvantages of each.
  • oleyl glycerate (OG) and phytanyl glycerate (PG) can form liquid crystals well, they are not used as excipients for pharmaceuticals due to their relatively high toxicity. Although this is possible, it has a disadvantage in that it cannot form sustained-release liquid crystals required for pharmaceuticals due to its low ability to form liquid crystals.
  • GDO glycerin diolate
  • WO 2005/117830 International Patent Publication No. WO 2005/117830 described above is in the form of a glyceride having a diacyl group, and although glycerin is used as a polar head part, it is generally not used as an excipient for pharmaceuticals because of its safety. There is a problem in that the material is not sufficiently secured.
  • liquid crystals formed by sorbitan unsaturated fatty acid esters are not only very advantageous for sustained release of the active material, but also have superior safety compared to existing liquid crystal forming materials.
  • liquid crystals formed by sorbitan unsaturated fatty acid esters are not only very advantageous for sustained release of the active material, but also have superior safety compared to existing liquid crystal forming materials.
  • biodegradability is an essential element.
  • biodegradability is a very important factor.
  • the sustained-release effect is shown for 1 week, ideally after 1 week, it is desirable that the injected PLGA is decomposed and disappears in the living body. There is a problem that persists without decomposition from up to several months. Therefore, it is clear that the sorbitan unsaturated fatty acid ester of the present invention, which has excellent sustained-release properties, secures safety, and is also excellent in biodegradability, is a new liquid crystal forming material having a very high industrial value.
  • the sorbitan unsaturated fatty acid ester of the present invention is a vegetable oil (eg, palm oil, castor oil, olive oil, peanut oil, rapeseed oil, corn oil, sesame oil, cottonseed oil, soybean oil, sunflower oil, safflower oil, linseed oil, etc.), Sorbitan monoester, sorbitan sesquiester, sorbitan derived from fatty acids obtainable from animal fats and oils (eg milk fat, pork fat and tallow) as well as whale oil and fish oil.
  • One or more sorbitan diesters and mixtures thereof may be selected.
  • the sorbitan monoester is one fatty acid group ester-bonded with sorbitan, sorbitan monooleate (sorbitan monooleate), sorbitan monolinoleate (sorbitan monolinoleate), sorbitan monopalmitolate (sorbitan) monopalmitoleate), sorbitan monomyristoleate, and at least one mixture thereof may be selected.
  • the sorbitan sesquiester is an ester bond of 1.5 fatty acid groups on average to sorbitan, and includes sorbitan sesquioleate, sorbitan sesquilinoleate, sorbitan sesquipalmi. Tolate (sorbitan sesquipalmitoleate), sorbitan sesquimyristoleate (sorbitan sesquimyristoleate), and at least one mixture thereof may be selected.
  • the sorbitan diester is an ester bond of two fatty acid groups to sorbitan, sorbitan dioleate, sorbitan dilinoleate, sorbitan dipalmitoleate ), sorbitan dimyristoleate, and mixtures thereof.
  • Sorbitan unsaturated fatty acid ester is sorbitan monooleate, sorbitan monolinoleate, sorbitan monopalmitoleate, sorbitan monomyristoleate ), sorbitan sesquioleate, and mixtures thereof are preferably used.
  • the phospholipid of the present invention is a material that has been essentially used for the production of a lamellar structure such as a liposome in the prior art, but independently has a non-lamellar phase structure in a liquid phase Crystals cannot be formed.
  • the phospholipid plays a role in stabilizing the liquid crystal by participating in the non-lamellar structure triggered by the sorbitan unsaturated fatty acid ester, which is the liquid crystal forming agent of the present invention.
  • the phospholipid of the present invention is a plant or animal-derived form, and specifically has an alkyl ester group having 4 to 30 saturated or unsaturated carbon atoms, and phosphatidylcholine, phosphatidylethanolamine depending on the structure of the polar head part. (phosphatidylethanolamine), phosphatidylserine, phosphatidylglycerine, phosphatidylinositol and phosphatidic acid, one or more sphingomyelin and mixtures thereof may be selected.
  • phospholipid is a form derived from plants or animals such as soybean or egg, and the alkyl ester group bonded to phospholipid is mono- and dipalmitoyl, mono- and dimyristoyl (mono- and dimyristoyl). and dimyristoyl), mono- and dilauryl, mono- and distearyl, saturated fatty acid esters or mono- or dilinoleyl, mono- and dioleyl ( There are unsaturated fatty acid esters such as mono- and dioleyl, mono- and dipalmitoleyl, mono- and dimyristoleyl, or saturated fatty acid esters and unsaturated fatty acid esters. may be in the form
  • the liquid crystal strengthening agent of the present invention is actually very specific, and can be administered to the human body only through direct and repeated experiments and a material suitable for the living body can be selected.
  • the liquid crystal strengthening agent suitable for the composition of the present invention is Each of them had a different molecular structure, so it could not be explained by a single structure.
  • the hydrophobic portion does not have an ionizing group such as a carboxyl group or an amine group and has a total carbon number of 15 to 40 bulky tria It was confirmed that the material had a real group or a carbon ring structure.
  • the liquid crystal strengthening agent of the present invention is triglyceride, retinyl palmitate, tocopherol acetate, cholesterol, benzyl benzoate, ubiquinone, and One or more of these mixtures may be selected, but the present invention is not limited thereto.
  • tocopherol acetate, cholesterol, or a mixture thereof may be the liquid crystal strengthening agent of the present invention.
  • the water of the present invention serves to rapidly form a liquid crystal gel immediately after the liquid injection is administered.
  • the lipid initial formulation without water draws moisture in the living body and forms a liquid crystal gel very slowly. Because it forms a liquid crystal gel at a slow rate, it spreads widely in the injection site, and in that state, a liquid crystal gel is formed to form a gel with a large surface area or to form a fragmented gel.
  • a liquid crystal gel having a large surface area or fragmented liquid crystal gel causes dumping of the drug at the initial stage of administration, which results in insufficient drug release in the late stage of the sustained-release period, making it difficult to maintain stable sustained-release properties for a long period of time.
  • the initial formulation of the lipid contains water, it rapidly forms a gel upon administration to the tissue to lower the initial release rate of the drug, thereby providing stable sustained release of the drug.
  • water may be added as water for injection, distilled water, buffer, or a mixture of two or more selected among them.
  • GnRH analogues are structurally similar to GnRH, but act differently in the body. In general, GnRH performs a biological function of inducing the production of sex steroids in the body through pulsatile secretion, but GnRH derivatives are used to strongly inhibit the production of sex steroids in the body for a certain period of time.
  • GnRH derivatives can be classified into agonists or antagonists according to their mechanism of action.
  • a therapeutic dose of a GnRH agonist When a therapeutic dose of a GnRH agonist is administered into the body, the GnRH agonist initially binds to the GnRH receptor of the pituitary gonadotropin and promotes the biosynthesis and secretion of follicle-stimulating hormone (FSH) and progesterone (LH).
  • FSH follicle-stimulating hormone
  • LH progesterone
  • continuous administration of a GnRH agonist depletes gonadotropin, while down-regulating the GnRH receptor has the function of inhibiting the biosynthesis and secretion of follicle stimulating hormone (FSH) and progesterone (LH).
  • GnRH derivatives can be used for prostate cancer, breast cancer, ovarian cancer, endometriosis, fibroids of the uterus, polycystic ovaryosis, hirsutism, precocious puberty, gonadotropic pituitary adenoma, sleep apnea, irritable bowel syndrome, and premenstrual syndrome.
  • GnRH agonist that can be used as a pharmacologically active material of the present invention is leuprolide, goserelin, triptorelin, nafarelin, buserelin ), histrelin, deslorelin, meterelin, gonadrelin, or a pharmacologically acceptable salt thereof may be selected.
  • one or more pharmacologically active substances may be selected from leuprolide, goserelin, and pharmacologically acceptable salts thereof.
  • GnRH antagonists competitively respond to the GnRH receptor of the pituitary gonadotropin and block the binding of GnRH in the body, thereby inhibiting the biosynthesis and secretion of follicle-stimulating hormone (FSH) and progesterone (LH).
  • FSH follicle-stimulating hormone
  • LH progesterone
  • GnRH antagonists that can be used as pharmacologically active substances of the present invention are degarelix, abarelix, ganirelix, cetrorelix and their pharmacologically acceptable salts.
  • one or more pharmacologically active substances may be selected from degarelix and pharmacologically acceptable salts thereof.
  • composition for injection of the present invention may further include a solvent in addition to a) to e).
  • a solvent may be ethanol, dimethyl sulfoxide (DMSO), benzyl alcohol, benzyl benzoate, methylpyrrolidone or propylene glycol, and these may be used alone or in combination of two or more.
  • the weight ratio of component a) and component b) suitable for the desired liquid crystal of the composition for injection of the present invention is 10:1 to 1:10, specifically, 5:1 to 1:5.
  • the weight ratio of component a)+b) and component c) is from 100:1 to 1:1, and may be, for example, from 50:1 to 2:1.
  • the sustained-release effect by the liquid crystal desired in the present invention may be good, and it is possible to control the sustained-release pattern by controlling their ratio.
  • the weight ratio of components a) + b) + c) and d) suitable for the desired liquid crystal of the injectable composition of the present invention is 99:1 to 1:1, for example, 99:1 to 90:10 or 75:25 to 62.5:37.5.
  • the weight ratio of components a) + b) + c) + d) and component e) suitable for the desired liquid crystal of the injectable composition of the present invention is 10000:1 to 1:1, for example, 1000:1 to It is 1:1.
  • the content of one component expressed as “wt%” means that the weight of the component accounts for 100% of the total weight of the injectable composition.
  • the injectable composition of the present invention may include an extra solvent along with components a) to e).
  • the injectable composition of the present invention is a) 9 to 90% by weight; b) 9 to 90% by weight; c) 0.1 to 50% by weight; d) 0.5 to 50% by weight and e) 0.01 to 50% by weight.
  • the injectable composition of the present invention comprises a) 9 to 50% by weight; b) 18 to 60% by weight; c) 1 to 36% by weight; d) 0.5 to 50% by weight; and e) 0.1 to 45% by weight.
  • the injectable composition of the present invention comprises a) 9 to 50% by weight; b) 18 to 60% by weight; c) 1 to 36% by weight; d) 0.5 to 10.5% by weight; and e) 0.1 to 45% by weight.
  • the injectable composition of the present invention comprises a) 9 to 50% by weight; b) 18 to 60% by weight; c) 1 to 36% by weight; d) 2.5 to 10.5% by weight; and e) 0.1 to 45% by weight.
  • the composition for injection of the present invention comprises a) 9 to 50% by weight; b) 18 to 60% by weight; c) 1 to 36% by weight; d) 0.5 to 10.5% by weight or 25 to 37.5% by weight; and e) 0.1 to 45 wt% of leuprolide or a pharmaceutically acceptable salt thereof.
  • Sorbitan unsaturated fatty acid ester (sorbitan unsaturated fatty acid ester), phospholipid, liquid crystal strengthening agent, water, and pharmacologically active substances were added at the same weight as in Table 1 below.
  • Comparative Examples 2 and 10 of the present invention the gel properties in the subcutaneous tissue of the mini pig were confirmed.
  • the experiment was performed by administering 0.3 mL each of the compositions of Comparative Examples 2 and 10 using a disposable syringe under the back skin of a mini pig (male) weighing about 15 kg. After 7 days had elapsed after administration, the administration site was excised, and the results of comparative observation of the gel properties are shown in FIG. 3 .
  • Example 13 lowered the initial drug dumping phenomenon and maintained a higher drug blood concentration than the composition of Comparative Example 3 for 1 month while the drug remained in the gel formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une composition injectable de la présente invention présente une sécurité remarquablement accrue par formation, dans une composition, d'un ester d'acide gras insaturé de sorbitane présentant une tête polaire pourvue de deux groupes -OH (hydroxyle) ou plus, se trouvant dans une phase liquide dans une phase où un fluide aqueux est absent de façon à être facilement appliqué à des préparations pharmaceutiques dans des formes posologiques et formant un cristal liquide dans une phase fluide aqueuse de telle sorte que des effets de libération prolongée de dérivés de GnRH, qui sont utilisés en tant que principe pharmaceutiquement actif in vivo, sont présentés. De plus, dans une composition injectable de la présente invention, un préconcentrat lipidique à libération prolongée comprenant des dérivés de GnRH comprend de l'eau et ainsi un agent injectable liquide forme un gel à cristaux liquides immédiatement après l'administration, de sorte que les effets de réduction de la vitesse de libération initiale et d'augmentation remarquable des propriétés de libération prolongée du médicament sont présentés.
PCT/KR2021/008187 2020-06-30 2021-06-29 Composition injectable comprenant des dérivés de gnrh WO2022005169A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202180046461.0A CN115867258A (zh) 2020-06-30 2021-06-29 包含GnRH衍生物的可注射组合物
AU2021299156A AU2021299156A1 (en) 2020-06-30 2021-06-29 Injectable composition comprising GnRH analogue
US18/010,399 US20230248801A1 (en) 2020-06-30 2021-06-29 INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE
CA3180468A CA3180468A1 (fr) 2020-06-30 2021-06-29 Composition injectable comprenant des derives de gnrh
EP21833046.2A EP4173614A1 (fr) 2020-06-30 2021-06-29 Composition injectable comprenant des dérivés de gnrh
MX2022016437A MX2022016437A (es) 2020-06-30 2021-06-29 Composicion inyectable que comprende un analogo de gnrh.
JP2022581316A JP2023532107A (ja) 2020-06-30 2021-06-29 Ｇｎｒｈ誘導体を含む注射用組成物
BR112022025817A BR112022025817A2 (pt) 2020-06-30 2021-06-29 Composição injetável que compreende análogo de gnrh

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200080621 2020-06-30
KR10-2020-0080621 2020-06-30

Publications (1)

Publication Number Publication Date
WO2022005169A1 true WO2022005169A1 (fr) 2022-01-06

Family

ID=79316601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/008187 WO2022005169A1 (fr) 2020-06-30 2021-06-29 Composition injectable comprenant des dérivés de gnrh

Country Status (10)

Country Link
US (1) US20230248801A1 (fr)
EP (1) EP4173614A1 (fr)
JP (1) JP2023532107A (fr)
KR (1) KR102628523B1 (fr)
CN (1) CN115867258A (fr)
AU (1) AU2021299156A1 (fr)
BR (1) BR112022025817A2 (fr)
CA (1) CA3180468A1 (fr)
MX (1) MX2022016437A (fr)
WO (1) WO2022005169A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003291A1 (fr) * 2022-06-30 2024-01-04 Virbac Utilisation de desloréline dans la castration chimique d'un mammifère non humain lié à une interaction pharmacocinétique/pharmacodynamique

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480656A (en) 1990-02-13 1996-01-02 Takeda Chemical Industries, Ltd. Prolonged release microcapsules
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5888533A (en) 1995-10-27 1999-03-30 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6773714B2 (en) 1998-10-28 2004-08-10 Atrix Laboratories, Inc. Polymeric delivery formulations of leuprolide with improved efficacy
WO2005074896A1 (fr) 2004-02-10 2005-08-18 Takeda Pharmaceutical Company Limited Preparation pour liberation soutenue
WO2005117830A1 (fr) 2004-06-04 2005-12-15 Camurus Ab Formulations de depot lipidique
WO2006075125A1 (fr) 2005-01-14 2006-07-20 Camurus Ab Formulations d'analogues de gnrh
US20070080323A1 (en) * 2003-11-07 2007-04-12 Fedrik Joabsson Compositions of lipids and cationic peptieds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7871642B2 (en) 1998-05-11 2011-01-18 Ciba Specialty Chemicals Corporation Use of nanodispersions in pharmaceutical end formulations
WO2012160212A1 (fr) 2011-05-25 2012-11-29 Camurus Ab Formulation de peptides à libération contrôlée
KR20130024804A (ko) * 2011-08-30 2013-03-08 주식회사종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR20140086741A (ko) * 2012-12-28 2014-07-08 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR20190036449A (ko) * 2017-09-27 2019-04-04 주식회사 제이피바이오지 지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480656A (en) 1990-02-13 1996-01-02 Takeda Chemical Industries, Ltd. Prolonged release microcapsules
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5888533A (en) 1995-10-27 1999-03-30 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US7871642B2 (en) 1998-05-11 2011-01-18 Ciba Specialty Chemicals Corporation Use of nanodispersions in pharmaceutical end formulations
US6773714B2 (en) 1998-10-28 2004-08-10 Atrix Laboratories, Inc. Polymeric delivery formulations of leuprolide with improved efficacy
US20070080323A1 (en) * 2003-11-07 2007-04-12 Fedrik Joabsson Compositions of lipids and cationic peptieds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2005074896A1 (fr) 2004-02-10 2005-08-18 Takeda Pharmaceutical Company Limited Preparation pour liberation soutenue
US20070265190A1 (en) 2004-06-04 2007-11-15 Krister Thuresson Opioid depot formulations
WO2005117830A1 (fr) 2004-06-04 2005-12-15 Camurus Ab Formulations de depot lipidique
WO2006075125A1 (fr) 2005-01-14 2006-07-20 Camurus Ab Formulations d'analogues de gnrh
WO2012160212A1 (fr) 2011-05-25 2012-11-29 Camurus Ab Formulation de peptides à libération contrôlée
KR20130024804A (ko) * 2011-08-30 2013-03-08 주식회사종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR20140086741A (ko) * 2012-12-28 2014-07-08 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR20190036449A (ko) * 2017-09-27 2019-04-04 주식회사 제이피바이오지 지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. SAHY. BAHL, JOURNAL OF CONTROLLED RELEASE, vol. 106, 2005, pages 51 - 61
K. ATHANASIOUG. G. NIEDERAUERC. M. AGRAWAL, BIOMATERIALS, vol. 17, 1996, pages 93
KHAN UROOJ AHMED, PARVEEN UZMA, HASAN NAZEER, AHMED MOHAMMAD ZUBAIR, SAAD SUMA, AHMAD FARHAN JALEES, JAIN GAURAV KUMAR: "Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. Volume 14, 9 June 2020 (2020-06-09), pages 2237 - 2247, XP055883560, DOI: 10.2147/DDDT.S247196 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003291A1 (fr) * 2022-06-30 2024-01-04 Virbac Utilisation de desloréline dans la castration chimique d'un mammifère non humain lié à une interaction pharmacocinétique/pharmacodynamique

Also Published As

Publication number Publication date
AU2021299156A1 (en) 2023-01-19
KR102628523B1 (ko) 2024-01-24
CA3180468A1 (fr) 2022-01-06
US20230248801A1 (en) 2023-08-10
BR112022025817A2 (pt) 2023-01-10
EP4173614A1 (fr) 2023-05-03
CN115867258A (zh) 2023-03-28
KR20220002140A (ko) 2022-01-06
MX2022016437A (es) 2023-01-30
JP2023532107A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
KR101586791B1 (ko) ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2014104784A1 (fr) Préconcentré lipidique à libération prolongée d'une substance cationique pharmacologiquement active et composition pharmaceutique le comprenant
KR101494594B1 (ko) 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
JP5671451B2 (ja) ＧｎＲＨ関連化合物の組成物および調製プロセス
KR100217258B1 (ko) 경비조성물
SK16552002A3 (sk) Stála, biologicky zlúčiteľná, dobre znášateľná mikroemulzia voda v oleji a jej použitie
KR20070001876A (ko) 주사가능한 지속된 약물 전달 비히클로서의 계면활성제계겔
WO2020171491A1 (fr) Préformulation lipidique à libération prolongée et composition pharmaceutique pour injection à libération prolongée sous la forme d'une solution lipidique contenant celle-ci
WO2014104788A1 (fr) Pré-concentré lipidique à libération prolongée de substances anioniques pharmacologiquement actives et composition pharmaceutique le contenant
WO2022005169A1 (fr) Composition injectable comprenant des dérivés de gnrh
WO2023080712A1 (fr) Nouveau pré-concentré de lipide à libération prolongée et composition pharmaceutique injectable à libération prolongée le comprenant
AU2019395549B2 (en) Composition comprising dutasteride
WO2002009670A1 (fr) Excipient pharmaceutique liquide ou semi-solide et composition pharmaceutique comprenant cet excipient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21833046

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3180468

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022581316

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022025817

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112022025817

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221216

ENP Entry into the national phase

Ref document number: 2021299156

Country of ref document: AU

Date of ref document: 20210629

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202317005594

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021833046

Country of ref document: EP

Effective date: 20230130